2024-09-012025-07-312025-07-31false11531430A NEW BEGINNING THERAPIES LIMITED2025-08-0786900falseiso4217:GBPxbrli:pure115314302024-08-31115314302025-07-31115314302024-09-012025-07-31115314302023-08-31115314302024-08-31115314302023-09-012024-08-3111531430bus:SmallEntities2024-09-012025-07-3111531430bus:AuditExempt-NoAccountantsReport2024-09-012025-07-3111531430bus:AbridgedAccounts2024-09-012025-07-3111531430bus:PrivateLimitedCompanyLtd2024-09-012025-07-3111531430core:WithinOneYear2025-07-3111531430core:AfterOneYear2025-07-3111531430core:WithinOneYear2024-08-3111531430core:AfterOneYear2024-08-3111531430core:ShareCapital2025-07-3111531430core:SharePremium2025-07-3111531430core:RevaluationReserve2025-07-3111531430core:OtherReservesSubtotal2025-07-3111531430core:RetainedEarningsAccumulatedLosses2025-07-3111531430core:ShareCapital2024-08-3111531430core:SharePremium2024-08-3111531430core:RevaluationReserve2024-08-3111531430core:OtherReservesSubtotal2024-08-3111531430core:RetainedEarningsAccumulatedLosses2024-08-3111531430core:LandBuildings2025-07-3111531430core:PlantMachinery2025-07-3111531430core:Vehicles2025-07-3111531430core:FurnitureFittings2025-07-3111531430core:OfficeEquipment2025-07-3111531430core:NetGoodwill2025-07-3111531430core:IntangibleAssetsOtherThanGoodwill2025-07-3111531430core:ListedExchangeTraded2025-07-3111531430core:UnlistedNon-exchangeTraded2025-07-3111531430core:LandBuildings2024-08-3111531430core:PlantMachinery2024-08-3111531430core:Vehicles2024-08-3111531430core:FurnitureFittings2024-08-3111531430core:OfficeEquipment2024-08-3111531430core:NetGoodwill2024-08-3111531430core:IntangibleAssetsOtherThanGoodwill2024-08-3111531430core:ListedExchangeTraded2024-08-3111531430core:UnlistedNon-exchangeTraded2024-08-3111531430core:LandBuildings2024-09-012025-07-3111531430core:PlantMachinery2024-09-012025-07-3111531430core:Vehicles2024-09-012025-07-3111531430core:FurnitureFittings2024-09-012025-07-3111531430core:OfficeEquipment2024-09-012025-07-3111531430core:NetGoodwill2024-09-012025-07-3111531430core:IntangibleAssetsOtherThanGoodwill2024-09-012025-07-3111531430core:ListedExchangeTraded2024-09-012025-07-3111531430core:UnlistedNon-exchangeTraded2024-09-012025-07-3111531430core:MoreThanFiveYears2024-09-012025-07-3111531430core:Non-currentFinancialInstruments2025-07-3111531430core:Non-currentFinancialInstruments2024-08-3111531430dpl:CostSales2024-09-012025-07-3111531430dpl:DistributionCosts2024-09-012025-07-3111531430core:LandBuildings2024-09-012025-07-3111531430core:PlantMachinery2024-09-012025-07-3111531430core:Vehicles2024-09-012025-07-3111531430core:FurnitureFittings2024-09-012025-07-3111531430core:OfficeEquipment2024-09-012025-07-3111531430dpl:AdministrativeExpenses2024-09-012025-07-3111531430core:NetGoodwill2024-09-012025-07-3111531430core:IntangibleAssetsOtherThanGoodwill2024-09-012025-07-3111531430dpl:GroupUndertakings2024-09-012025-07-3111531430dpl:ParticipatingInterests2024-09-012025-07-3111531430dpl:GroupUndertakingscore:ListedExchangeTraded2024-09-012025-07-3111531430core:ListedExchangeTraded2024-09-012025-07-3111531430dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-09-012025-07-3111531430core:UnlistedNon-exchangeTraded2024-09-012025-07-3111531430dpl:CostSales2023-09-012024-08-3111531430dpl:DistributionCosts2023-09-012024-08-3111531430core:LandBuildings2023-09-012024-08-3111531430core:PlantMachinery2023-09-012024-08-3111531430core:Vehicles2023-09-012024-08-3111531430core:FurnitureFittings2023-09-012024-08-3111531430core:OfficeEquipment2023-09-012024-08-3111531430dpl:AdministrativeExpenses2023-09-012024-08-3111531430core:NetGoodwill2023-09-012024-08-3111531430core:IntangibleAssetsOtherThanGoodwill2023-09-012024-08-3111531430dpl:GroupUndertakings2023-09-012024-08-3111531430dpl:ParticipatingInterests2023-09-012024-08-3111531430dpl:GroupUndertakingscore:ListedExchangeTraded2023-09-012024-08-3111531430core:ListedExchangeTraded2023-09-012024-08-3111531430dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-09-012024-08-3111531430core:UnlistedNon-exchangeTraded2023-09-012024-08-3111531430core:NetGoodwill2025-07-3111531430core:IntangibleAssetsOtherThanGoodwill2025-07-3111531430core:LandBuildings2025-07-3111531430core:PlantMachinery2025-07-3111531430core:Vehicles2025-07-3111531430core:FurnitureFittings2025-07-3111531430core:OfficeEquipment2025-07-3111531430core:AfterOneYear2025-07-3111531430core:WithinOneYear2025-07-3111531430core:ListedExchangeTraded2025-07-3111531430core:UnlistedNon-exchangeTraded2025-07-3111531430core:ShareCapital2025-07-3111531430core:SharePremium2025-07-3111531430core:RevaluationReserve2025-07-3111531430core:OtherReservesSubtotal2025-07-3111531430core:RetainedEarningsAccumulatedLosses2025-07-3111531430core:NetGoodwill2024-08-3111531430core:IntangibleAssetsOtherThanGoodwill2024-08-3111531430core:LandBuildings2024-08-3111531430core:PlantMachinery2024-08-3111531430core:Vehicles2024-08-3111531430core:FurnitureFittings2024-08-3111531430core:OfficeEquipment2024-08-3111531430core:AfterOneYear2024-08-3111531430core:WithinOneYear2024-08-3111531430core:ListedExchangeTraded2024-08-3111531430core:UnlistedNon-exchangeTraded2024-08-3111531430core:ShareCapital2024-08-3111531430core:SharePremium2024-08-3111531430core:RevaluationReserve2024-08-3111531430core:OtherReservesSubtotal2024-08-3111531430core:RetainedEarningsAccumulatedLosses2024-08-3111531430core:NetGoodwill2023-08-3111531430core:IntangibleAssetsOtherThanGoodwill2023-08-3111531430core:LandBuildings2023-08-3111531430core:PlantMachinery2023-08-3111531430core:Vehicles2023-08-3111531430core:FurnitureFittings2023-08-3111531430core:OfficeEquipment2023-08-3111531430core:AfterOneYear2023-08-3111531430core:WithinOneYear2023-08-3111531430core:ListedExchangeTraded2023-08-3111531430core:UnlistedNon-exchangeTraded2023-08-3111531430core:ShareCapital2023-08-3111531430core:SharePremium2023-08-3111531430core:RevaluationReserve2023-08-3111531430core:OtherReservesSubtotal2023-08-3111531430core:RetainedEarningsAccumulatedLosses2023-08-3111531430core:AfterOneYear2024-09-012025-07-3111531430core:WithinOneYear2024-09-012025-07-3111531430core:Non-currentFinancialInstrumentscore:CostValuation2024-09-012025-07-3111531430core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-09-012025-07-3111531430core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-09-012025-07-3111531430core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-09-012025-07-3111531430core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-09-012025-07-3111531430core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-09-012025-07-3111531430core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-09-012025-07-3111531430core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-09-012025-07-3111531430core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-09-012025-07-3111531430core:Non-currentFinancialInstrumentscore:CostValuation2025-07-3111531430core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-07-3111531430core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-07-3111531430core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-07-3111531430core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-07-3111531430core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-07-3111531430core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-07-3111531430core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-07-3111531430core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-07-3111531430core:Non-currentFinancialInstrumentscore:CostValuation2024-08-3111531430core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-08-3111531430core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-08-3111531430core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-08-3111531430core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-08-3111531430core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-08-3111531430core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-08-3111531430core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-08-3111531430core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-08-3111531430bus:Director12024-09-012025-07-3111531430bus:Director22024-09-012025-07-311153143012024-09-012025-07-31

A NEW BEGINNING THERAPIES LIMITED

Registered Number
11531430
(England and Wales)

Unaudited Financial Statements for the Period ended
31 July 2025

A NEW BEGINNING THERAPIES LIMITED
Company Information
for the period from 1 September 2024 to 31 July 2025

Directors

ADAMS, Scott Nicholas
WEYMES, Amanda Jane

Registered Address

Lindsay House
15-17 Springfield Way
Anlaby
HU10 6RJ

Registered Number

11531430 (England and Wales)
A NEW BEGINNING THERAPIES LIMITED
Statement of Financial Position
31 July 2025

Notes

31 Jul 2025

31 Aug 2024

£

£

£

£

Fixed assets
Tangible assets3-1,477
-1,477
Current assets
Debtors-5,161
Cash at bank and on hand15,04467,071
15,04472,232
Prepayments and accrued income-2,015
Creditors amounts falling due within one year4(6,266)(49,482)
Net current assets (liabilities)8,77824,765
Total assets less current liabilities8,77826,242
Creditors amounts falling due after one year-(11,363)
Net assets8,77814,879
Capital and reserves
Called up share capital22
Profit and loss account8,77614,877
Shareholders' funds8,77814,879
The financial statements were approved and authorised for issue by the Board of Directors on 7 August 2025, and are signed on its behalf by:
ADAMS, Scott Nicholas
Director
WEYMES, Amanda Jane
Director

Registered Company No. 11531430
A NEW BEGINNING THERAPIES LIMITED
Notes to the Financial Statements
for the period ended 31 July 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).The financial statements have been prepared on a basis other than going concern.
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Revenue from rendering of services
Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
Current taxation
Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:
2.Average number of employees
The average number of persons employed by the company during the year amounted to

20252024
Average number of employees during the year22
3.Tangible fixed assets

Total

£
Cost or valuation
At 01 September 245,061
Disposals(5,061)
Depreciation and impairment
At 01 September 243,584
On disposals(3,584)
Net book value
At 31 July 25-
At 31 August 241,477
4.Creditors: amounts due within one year

2025

2024

££
Trade creditors / trade payables6933,164
Bank borrowings and overdrafts810,522
Taxation and social security4,80315,139
Accrued liabilities and deferred income76220,657
Total6,26649,482
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
5.Events after reporting date
The financial statements have been prepared on a cessation basis following the Director's decision to cease trading and apply for voluntary strike off under section 1003 of the Companies Act 2006. The company ceased trading on the 30th April 2025. The remaining assets of the company amounted to £1,100 and were distributed to the shareholders as a capital distribution in anticipation of strike off. Since the balance sheet date, the company has commenced settlement of its remaining liabilities. The corporation tax liability and trade creditors will be fully settled, and any remaining bank balance will be withdrawn as final dividend prior to strike off.